非索非那定
药效团
组胺
药理学
组胺受体
受体
对接(动物)
组胺H1受体
化学
计算生物学
医学
生物
立体化学
敌手
生物化学
护理部
作者
Zaid Anis Sherwani,Mohammad Nur‐e‐Alam,Aftab Ahmed,Zaheer Ul‐Haq
出处
期刊:Medicinal Chemistry
[Bentham Science Publishers]
日期:2025-01-27
卷期号:21
标识
DOI:10.2174/0115734064355393250121062539
摘要
Introduction: Histamine Type I Receptor Antagonists (H1 blockers) are widely used to mitigate histamine-induced inflammation, particularly in allergic reactions. Histamine, a biogenic amine found in endothelial cells, vascular smooth muscle, bronchial smooth muscle, and the hypothalamus, is a key player in these responses. H1 blockers are essential in cough syrups and flu medications and are divided into two generations: first-generation H1 blockers, which are sedating and have numerous side effects, and second-generation blockers, which are non-sedating and generally less toxic but may still exhibit cross-reactivity with other receptors. Method: In this study, a comprehensive database of compounds was utilized alongside fexofenadine as a benchmark to discover compounds with potentially superior efficacy and reduced side effect profiles. In particular, multidimensional K-means clustering, a machine-learning technique, was applied to identify compounds with chemical structures similar to fexofenadine. Result: Utilizing computational prediction of pharmacokinetic profile and molecular docking experiments, the action of these drugs on the H1 receptor was assessed. Furthermore, the crossreactivity of antihistamines was investigated by conducting a structure-based pharmacophore feature analysis of the docked poses of highly toxic antihistamines with various receptors. Conclusion: By identifying and proposing the removal of common toxic features, we aim to facilitate the development of antihistamines with fewer adverse effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI